PT - JOURNAL ARTICLE AU - Shean, Ryan C. AU - Garrett, Elizabeth AU - Malleis, James AU - Lieberman, Joshua A. AU - Bradley, Benjamin T. TI - Impact of Diagnostic Stewardship on Ordering Trends and Pathogen Yield from mNGS Studies AID - 10.1101/2024.04.19.24306038 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.19.24306038 4099 - http://medrxiv.org/content/early/2024/04/22/2024.04.19.24306038.short 4100 - http://medrxiv.org/content/early/2024/04/22/2024.04.19.24306038.full AB - Background Given the cost and unclear clinical impact of metagenomic next-generation sequencing (mNGS), laboratory stewardship may improve utilization. This study examines mNGS results from two academic medical centers employing different stewardship approaches.Methods 80 mNGS orders (54 CSF and 26 plasma) were identified from 2019 to 2021 at the University of Washington (UW), which requires director-level approval for mNGS orders, and the University of Utah (Utah), which does not restrict ordering. The impact of mNGS results and the relationship to traditional microbiology orders were retrospectively evaluated.Results 19% (10/54) CSF and 65% (17/26) plasma studies detected at least one organism. Compared to CSF results, plasma results were more frequently clinically significant (23% vs 7%) and led to more novel diagnoses (15% vs 0%). Results affecting antibiotic management were more common for plasma than CSF (32% vs. 2%). Stewardship practices were not associated with statistically significant differences in results or antimicrobial management. The number and cost of traditional microbiology tests at UW was greater than Utah for CSF mNGS testing (UW: 46 tests, $6237; Utah: 26 tests, $2812; p<0.05) but similar for plasma mNGS (UW: 31 tests, $3975; Utah: 21 tests, $2715; p=0.14). mNGS testing accounted for 30-50% of the total microbiology costs.Conclusions Improving the diagnostic performance of mNGS by stewardship remains challenging due to low positivity rates and difficulties assessing clinical impact. From a fiscal perspective, stewardship efforts should focus on reducing testing in low-yield populations given the high costs of mNGS relative to overall microbiology testing expenditures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Washington (UW) Institutional Review Board Committee (IRB ID STUDY00010777) and University of Utah (Utah) Institutional Review Board (IRB 00151187) as waived research; informed consent was not required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors